the collagenase enhancer AP-1 consensus sequence and with a DNA fragment containing an altered AP-1 site. The binding of JUN/AP-1 was maximal at 1 hour of ara-C treatment and decreased t o baseline levels at 12 hours. The finding that ara-C induces AP-1 binding in the absence of protein synthesis indicated that this agent activates already synthesized JUN/AP-1. To confirm these findings, the AP-1 consensus sequence was introduced 5' t o the heterologous SV40 promoter. The results show that AP-1 enhances SV40 promoter activity in ara-Gtreated cells. Taken together, these findings indicate that: (1) consensus sequence TGAG/,TCA (TRE).l6.Iy The affinity of JUN/AP-1 for DNA binding is related to dimerization with other transcription factors that contain a leucine zipper. For example, while JUN homodimers activate the TRE, this effect is enhanced by the formation of heterodimers between JUN and C-FOS.*~~~~ TRE or AP-1 binding sites are known to be involved in the transcriptional regulation of various genes responsive to phorbol esters and growth factors. Indeed, the c-jun gene is positively autoregulated by its own product, JUNIAP-1."
The present studies show that the AP-1 site in the c-jun promoter mediates ara-C inducibility of the c-jun gene. Binding of ara-C-induced nuclear proteins to the AP-1 site in the absence of protein synthesis further indicates that this effect of ara-C involves activation of preexisting AP-1.
MATERIALS AND METHODS
Cell culture. Human KG-1 myeloid leukemia cells (American Type Culture Collection, Bethesda, MD) were grown in Isocove's medium supplemented with 15% heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 400 FgImL streptomycin (GIBCO Laboratories, Grand Island, NY). The cells were treated with mol/L ara-C (Sigma Chemical Co, St Louis, MO) and 100 U/mL tumor necrosis factor (TNF; Asahi Chemical Co, Tokyo, Japan). Human FH 109 lung fibroblasts were maintained as described" and treated with 100 U/mL TNF.
The SV40 and enhancer regions were excised from ~S v T 7 . 2~ Expression vectors were constructed by inserting the CAT gene into the multicloning Hind111 site. Fragments prepared by exonuclease 111 digestion of the c-jun promoter region2* (provided by P. Angel, Kernforschungszentrum, Karlsruhe, Germany) were inserted at the PstI site by blunt-ended DNA ligation. Sequencing of the deleted constructs was performed by the Maxam-Gilbert method.25 The AP-1 consensus sequence (CTAGTGATGAGTCAGCCGGATC) was also inserted into the BglI site of the pSV40 vector (provided by D. Johnson, Brigham and Women' Hospital, Boston, MA). All vectors used for transfection were purified twice by cesium chloride gradient centrifugation.
Plasmids were transfected into KG-1 cells using the diethyl aminoethyl (DEE)-dextran technique. 26 The cells were harvested 36 hours after transfection and maintained for an additional 10 hours in the presence or absence of lo-' mol/L ara-C. CAT activity" was assayed in 200-kL reactions containing 100 FL of cell Reporter assays. extract, 0.025 kCi ['4C]chloramphenicol (Amersham, Arlington Heights, IL; 57 mciimmol), 275 mmol/L Tris-HC1, pH 7.8, and 0.4 mmol/L acetylcoenzyme A for 2 hours at 37°C. The acetylated products were separated from unacetylated chloramphenicol by thin-layer chromatography. Both unacetylated and acetylated forms of ['4CC]chloramphenicol were cut from the thin-layer chromatography plate and radioactivity determined by scintillation counting. Protein concentration as determined by the Bradford protein assayzx was used to normalize conversion of chloramphenicol to its acetylated forms.
Nuclear proteins were prepared according to described methods." In certain experiments, the nuclear proteins were incubated for 30 minutes at 37°C in the presence of a monoclonal antibody (MAb) directed against the binding epitope of JUN/AP-1 (Oncogene Science, Inc, Manhasset, NY). The 54-bp StyIISacI fragment of the cjun promoter (positions -74 and -20) was end-labeled with [a--'*P]dATP using DNA polymerase I. This fragment was either purified in a 12% polyacrylamide gel or digested with HincII to generate a 30-bp StyIiHincII fragment (GGGGTGACATCATGGGCTATTTTTAGGGGT) which was also purified by gel electrophoresis. The end-labeled DNA (1 ng; -2 x lo5 cpm) was incubated with 10 kg nuclear protein for 20 minutes at 20°C in a buffer containing 25 mmol/L Tris-HCI, pH 7.6,5 mmol/L MgCI,, 0.5 mmol/L EDTA, 1 mmol/L D I T , and 10% (vol/vol) glycerol. Competition studies with oligonucleotides corresponding to NF-1, Spl, AP-1, AP-2, and AP-3 binding sites (Strategene, La Jolla, CA) were performed by adding up to a 200-fold molar excess compared with the labeled fragment. The reaction products were analyzed by 5% polyacrylamide gel electrophoresis and autoradiography.
Electrophoretic mobility shift assays.
RESULTS
The c-jun gene is transcriptionally activated during treatment of human myeloid leukemia cells with ara-C. Because previous studies have shown that the c-jun gene is autoinduced by its product JUN/AP-l,*' the present work first examined whether the effects of ara-C involve activation of the AP-1 consensus sequeoce between positions -72 and -63 in the c-jun promoter. To address this issue, we prepared promoter fragments that included -74 bp and -20 bp upstream to the transcription start site. These fragments were ligated to the CAT gene ( Fig 1A) and transfected into KG-1 cells. Transfection of the p-74CAT vector into unstimulated cells showed a basal level of transcription that was increased from 2.5-to 4-fold after ara-C treatment (Fig 1B) . In contrast, transfection of the p-20CAT vector demonstrated a relatively lower level of CAT activity that was similar in both unstimulated and ara-C-treated cells (Fig 1B) . These findings indicated that ara-C-induced c-jun transcription is mediated by an element between positions -74 and -20.
To determine whether additional elements upstream to the AP-1 site function in ara-C inducibility of the c-jun gene, other promoter-CAT constructs were prepared that included -286 bp upstream to the start site. Transfection of p-286CAT, p-l66CAT, and p-128CAT vectors into ara-Ctreated cells was associated with a 2.2-, 2.4-, and 3.1-fold increase, respectively, in CAT activity as compared with that in untreated cells (Fig 2) . In these experiments, expression of the p-74CAT construct was increased threefold in ara-C-treated cells, while there was no detectable effect of this agent on transcription of the p-20CAT vector (Fig 2) . Other studies were performed to determine the effects of altering the AP-1 binding site in the c-jun promoter. Digestion of f( -128/ +286) with Mae111 and then religation of the fragments resulted in partial deletion of the AP-1 sequence (TGGGGTGACATCAT to TGG-GATCAT). Transfection of this fragment linked to the CAT gene, p(de1AP-l)CAT, into untreated and ara-Ctreated cells resulted in similar levels of CAT activity (Fig  2) . Taken together, these findings provided further evidence that activation of the c-jun gene by ara-C is mediated by the AP-1 element.
The results of the CAT assays prompted on analysis of the interaction between ara-C-induced nuclear proteins and potential cis-regulatory elements. The region of the c-jun promoter between positions -74 and -20 contains the AP-1 consensus sequence, as well as two TATA-like elements." To identify the DNA binding factor(s) mediating ara-C inducibility, we performed electrophoretic mobility shift assays (EMSAs) using the fragment f(-74/-20). Incubation of end-labeled f( -74/ -20) with nuclear proteins from untreated KG-1 cells showed two faint but detectable retarded bands (Fig 3) . In contrast, the intensity of these bands was increased when using nuclear extracts from ara-C-treated cells (Fig 3) . KG-1 cells were also treated with TNF, an agent previously shown in myeloid cells to activate JUN/AP-1 binding to its consensus seq~e n c e . '~ A similar retardation pattern was obtained with nuclear proteins from TNF-treated KG-1 cells, although there appeared to be slight differences in the mobility of the retarded bands compared to that obtained with ara-C ( Fig   For personal use 
3). These results suggested that ara-C and TNF activate similar, but perhaps not identical, DNA binding complexes. While the EMSA findings suggested that ara-C treatment is associated with an increase in DNA binding of JUN/ AP-1, competition studies were performed with an oligonucleotide containing the AP-1 binding site. The AP-1 oligonucleotide decreased binding of nuclear proteins from both untreated and ara-C-treated cells (Fig 4A) . This competitive effect was concentration-dependent and nearly complete for both retarded bands when using a 200-fold excess of oligonucleotide (Fig 4B) . In contrast, there was no detectable effect when using a similar excess of oligonucleotides containing sites for NF-1, Spl, AP-2, or AP-3 (data not shown). Taken together, these findings suggested that ara-C stimulates binding of KG-1 nuclear proteins at the AP-1 site.
The effects of ara-C on binding of nuclear proteins to f(-74/-44) were detectable by 30 minutes and maximal by 1 hour (Fig 5A) . Longer exposures of this agent were associated with a progressive decrease in intensity of the retarded bands to a level at 12 hours comparable with that in control cells. Moreover, our previous studies showed that induction of cjun gene transcription by ara-C occurs in the absence of protein synthesis." In this regard, activation of protein binding to f(-74/-44) was identical at 1 hour in the absence or presence of cycloheximide (Fig 5B) . Furthermore, treatment with cycloheximide alone had no detectable effect on nuclear protein binding to f( -74/ -44) (data not shown). These results suggested that ara-C activates already synthesized JUN/AP-1 and that this activation process stimulates binding to the cjun promoter.
We also performed EMSAs with a sequence from the collagenase gene enhancer that contains another known AP-i binding site (GGAGCTTGATGAGTCAGCCG-GACTC). Incubation of this labeled oligonucleotide with nuclear proteins from untreated KG-1 cells showed a retarded band (Fig 6A) . The size of this band was increased when using nuclear extracts from ara-C-treated cells ( Fig  6A) . Moreover, a similar pattern was obtained when cells were treated with TNF (Fig 6A) . The binding of these nuclear proteins was completely blocked by adding a 25-molar excess of unlabeled f( -74/ -44) from the cjun promoter (data not shown). In contrast, there was no detectable retardation observed when these protein preparations were incubated with the StyIIHincII fragment of the cjun promoter (positions -74 to -44) that contains the altered AP-1 site (TGGGATCAT) (Fig 6A) . Other studies were performed with nuclear proteins from nonconfluent FH 109 lung fibroblasts that have been shown to constitutively express JUN/AP-l."U Incubation of these nuclear For personal use only. on January 10, 2018. by guest www.bloodjournal.org From proteins with the collagenase enhancer AP-1 site resulted in a pattern similar to that obtained with untreated KG-1 cells (Fig 6B) . Furthermore, stimulation of FH 109 cells with TNF resulted in the same pattern of increased retardation observed with ara-C-treated KG-1 cells. Finally, there was no detectable binding of FH 109 nuclear proteins to the StyI/HincII fragment with the altered AP-1 site (Fig 6B) .
While the results of EMSAs provided evidence for protein binding to the AP-1 site, two major complexes perhaps each composed of sub-bands were detectable with the ara-C-induced nuclear preparations. For example, (Fig 7) . In contrast, treatment of the ara-C-induced nuclear proteins with the anti-JUN antibody completely inhibited formation of the upper complexes and resulted in only a partial decrease in intensity of the lower band (Fig 7) . These findings indicated that the increase in AP-1 binding by ara-C is at least in part due to JUN/AP-1 and that other AP-1 proteins may contribute to this activity.
To further confirm the functional capacity of the AP-1 site in mediating ara-C inducibility, we ligated fragments with and without the AP-1 consensus sequence to a heterologous SV40 promoter-CAT construct. These vectors (Fig 8A) were transfected into unstimulated and ara-Ctreated cells. Ara-C treatment was associated with an increase in CAT activity when using the AP-l-containing construct. In contrast, there was no difference in CAT activity between unstimulated and ara-C-treated cells transfected with the AP-1-negative vector (Fig 8B) . The finding that AP-1 mediates ara-C inducibility with a heterologous promoter provides further support for the involvement of this element in signaling events activated by this agent.
DISCUSSION
Certain insights are presently available regarding the mechanism of action of ara-C. The inhibitory effects of ara-C on DNA replication are related to both the extent of incorporation into DNA and sequence of the DNA template. In this regard, DNA strands are progressively terminated by incorporation at sequences containing two, three, and four contiguous cytosine sites.3'-'2 These findings are consistent with the conformational and hydrogen bonding differences of the incorporated arabinose moiety"." altering reactivity of the 3' terminus and thereby slowing or terminating DNA chain elongation. The cellular response to this induction of DNA damage by ara-C is unclear. promoter is responsible for the induction of c-jun transcription by TPA. The present results suggest that a similar mechanism is responsible for induction of the c-jun gene in ara-C-treated cells. The high-affinity AP-1 site that confers TPA inducibility of the c-jun gene is similarly activated after treatment of KG-1 cells with ara-C. Evidence in support of this mechanism includes the results of transient expression assays using fragments of the c-jun promoter that include and exclude this element. Furthermore, we have found that this AP-1 binding site confers ara-C inducibility to the heterologous SV40 promoter. Taken together with the results of EMSAs, which demonstrate increased AP-1 binding of nuclear proteins from ara-C-treated cells, these findings indicate that ara-C stimulates c-jun transcription by activating JUN/AP-l binding.
Our previous studies showed that ara-C induces transcription of the c-jun gene in the presence of cycloheximide." In the present work, activation of AP-1 binding by ara-C was also detectable in the absence of protein synthesis. These results support a mechanism involving posttranslational modification of preexisting AP-1 protein that results in induction of c-jun transcription. The nature of the modification induced by ara-C is unknown. Treatment of a variety of cell types, including myeloid leukemia cells, with TPA is associated with activation of protein kinase C and induction of c-jun transcription in the absence of de novo protein These findings have raised the possibility that ara-C activates JUN/AP-1 by a protein kinase C-dependent mechanism. Indeed, recent studies have demonstrated that ara-C treatment is associated with the rapid induction of a protein kinase activity." Moreover, this kinase phosphorylates a synthetic peptide that has been used as a substrate for protein kinase C.3' However, further studies are needed to determine whether the ara-C-induced activity is due to protein kinase C or another kinase and whether this signaling pathway is involved in the activation of JUN/ AP-1.
The activation of JUN/AP-1 and the subsequent induction of c-jun transcription by ara-C is presumably initiated by incorporation of this agent into Indeed, the previous finding that ara-C residues are detectable in DNA strands at 30 minutes of exposure to this agent" is in concert with the rapid activation of JUN/AP-l binding observed in the present studies. The incorporation of ara-C into DNA is associated with both inhibition of DNA synthesis and alteration of chromatin ~tructure.6"~ We have similarly treated cells with aphidicolin, an inhibitor of DNA polymerase a that is not incorporated into DNA.40 While aphidicolin also resulted in complete inhibition of cell growth, the finding that this agent had little if any effect on induction of c-jun expression suggested that inhibition of DNA synthesis is not sufficient for activation of this gene." Therefore, termination of DNA strand elongation by the incorporated arabinosyl moiety and accumulation of strand breaks4' may represent the initial signals that stimulate a cascade of events as part of the cellular response to DNA damage. In this context, previous studies have shown that other DNA-damaging agents, such as UV light, induce the transcription of genes, including c-jun, which are also regulated through the activation of AP-1 binding sites.4'~~~ Moreover, we have recently found that ionizing radiation regulates transcription of the c-jun gene and that this effect is independent of protein synthesis." Similar findings have been obtained with etoposide, an inhibitor of topoisomerase 11.4' Thus, a variety of agents that induce DNA damage by distant mechanisms appear to be capable of stimulating a cellular response that includes activation of JUN/AP-1 and induction of c-jun transcription. This response may play a role in the repair of DNA damage or in the initiation of a genetic program associated with cell death.
